Letermovir denied as experimental or investigational by Humana?

Humana's specific coverage criteria for letermovir are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Letermovir as Experimental — and Why It's Appealable

Letermovir received FDA approval for CMV prophylaxis in specific transplant populations. An "experimental or investigational" denial from Humana typically means the plan's medical policy has not been updated to reflect current FDA labeling or guideline support, or that the patient's specific clinical situation (e.g., a transplant type or indication not listed in the plan's criteria) is being treated as off-label. Because letermovir has FDA approval for its primary indication, an experimental denial in that approved context is almost always overturnable on appeal.

## The Federal Legal Framework

Appeals of experimental denials carry the full weight of: - ERISA §503: full-and-fair review with a written clinical rationale for the denial; Humana must explain which evidence review determined the treatment experimental. - ACA §2719: independent external review by a qualified Independent Review Organization (IRO), available within approximately four months of denial. Experimental-denial external reviews have high reversal rates nationally. The expedited process applies when clinical urgency exists (e.g., active transplant prophylaxis window).

For employer-sponsored plans in states with strong anti-experimental-denial statutes, additional state protections may apply.

## Concrete Appeal Steps and Timeline

1. Request Humana's written clinical criteria: Humana must provide the specific evidence review or medical policy it used to classify letermovir as experimental. 2. Internal appeal: file within the denial letter's deadline (commonly 180 days). Request expedited review given the time-sensitive nature of post-transplant prophylaxis. 3. Peer-to-peer: the transplant prescriber should request an urgent peer-to-peer call with Humana's medical director. 4. External review: if denied internally, file for IRO external review immediately; experimental denials in the face of FDA approval are a core IRO reversal scenario.

## Documentation to Gather

• FDA approval evidence: reference the current FDA-approved prescribing information for letermovir; confirm the approved indication matches the patient's use case.
• Transplant clinical record: documentation of transplant type, date, immunosuppression protocol, CMV serostatus, and the treating team's clinical rationale.
• Prescriber letter: the transplant infectious disease specialist or transplant physician should explicitly state that letermovir is FDA-approved, that its use here is consistent with the approved labeling, and that the relevant transplant guideline organizations support its use in this clinical context.
• Guideline support: reference the applicable transplant society guideline organization (e.g., AST, AATM, ECIL) without citing specific statistics — confirm with the current published version.
• Humana's medical policy: obtain and review Humana's letermovir coverage policy to identify every criterion and address each in your appeal.

## Criteria-Mapping Structure

Build a rebuttal table. Left column: each element of Humana's experimental criteria. Right column: the specific clinical fact, FDA labeling reference, or guideline citation that refutes the experimental classification. The most powerful argument is the FDA-approval anchor — if the use is within the approved indication, the "experimental" label is factually incorrect and the IRO is highly likely to reverse. Lead with that argument in both the internal appeal and the external review request.